

PATENT COOPERATION TREATY

09/673305

PCT

From the INTERNATIONAL BUREAU

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

F.B. RICE & CO.
605 Darling Street
Balmain, NSW 2041
AUSTRALIE

Date of mailing (day/month/year) 08 November 2000 (08.11.00)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference 84411	
International application No. PCT/AU99/00285	International filing date (day/month/year) 16 April 1999 (16.04.99)

1. The following indications appeared on record concerning:		
<input checked="" type="checkbox"/> the applicant	<input type="checkbox"/> the inventor	<input type="checkbox"/> the agent <input type="checkbox"/> the common representative
Name and Address UNISEARCH LIMITED 221-227 Anzac Parade Kensington, NSW 2033 Australia	State of Nationality AU	State of Residence AU
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:		
<input type="checkbox"/> the person	<input type="checkbox"/> the name	<input checked="" type="checkbox"/> the address <input type="checkbox"/> the nationality <input type="checkbox"/> the residence
Name and Address UNISEARCH LIMITED Rupert Myers Building, 3 Level 2, Gate 14 Barker Street, UNSW Sydney, NSW 2052 Australia	State of Nationality AU	State of Residence AU
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	
3. Further observations, if necessary:		
4. A copy of this notification has been sent to:		
<input checked="" type="checkbox"/> the receiving Office	<input type="checkbox"/> the designated Offices concerned	
<input type="checkbox"/> the International Searching Authority	<input checked="" type="checkbox"/> the elected Offices concerned	
<input type="checkbox"/> the International Preliminary Examining Authority	<input type="checkbox"/> other:	

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer S. De Michiel
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C.20231
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing: 28 October 1999 (28.10.99)	
International application No.: PCT/AU99/00285	Applicant's or agent's file reference: 84411
International filing date: 16 April 1999 (16.04.99)	Priority date: 16 April 1998 (16.04.98)
Applicant: READ, Roger et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International preliminary Examining Authority on:
25 June 1999 (25.06.99)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer: J. Zahra Telephone No.: (41-22) 338.83.38
---	---

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU 99/00285**A. CLASSIFICATION OF SUBJECT MATTER**Int Cl⁶: C07D 307/58, A61K 31/34, A01N 43/08, C08F 224/00, C23F 14/02, 15/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
STN CAS ON-LINE SUBSTRUCTURE SEARCH**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	Chemical Abstracts 130:155029 "Antifouling of Shellfish and aquaculture apparatus and coatings containing isothiazolones", & WO 99/05227 See compounds disclosed RN:63025-35-4, 63025-36-5, 174862-78-3	1-3, 17, 23
P, X	Chemical Abstracts 130:111094 "Polymers Compositions Containing isothiazolone and furanone anti-fouling agents and molded articles made from them", & WO 99/01514. See compounds disclosed RN: 219640-53-6, 219640-54-7, 219640-55-8, 219640-56-9	1-3, 17, 18-20, 23

☒ Further documents are listed in the continuation of Box C☒ See patent family annex

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search
7 May 1999Date of mailing of the international search report
12 MAY 1999Name and mailing address of the ISA/AU
AUSTRALIAN PATENT OFFICE
PO BOX 200
WODEN ACT 2606
AUSTRALIA
Facsimile No.: (02) 6285 3929Authorized officer
S.R. IDRUS
Telephone No.: (02) 6283 2536

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 99/00285

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Chemical Abstracts 128:241398 "A new method for determining Surface concentrations of marine natural products on seaweeds", De Nys, R; Dworjany, S.A.; Steinberg, P.D., Mar. Ecol.: Prog. Ser (12 February 1998) 162, 79-87 See compounds disclosed RN: 63025-21-8, 63025-28-5, 63025-36-5, 66042-01-1	1-3, 17
X	Chemical Abstracts 124:234956 "Antifouling marine compositions of furanone compounds", & WO 96/01294 See compounds disclosed RN: 63025-36-5, 66042-01-1, 143140-80-1, 169200-40-2, 169274-84-4, 174862-78-3, 174862-80-7	1-3, 17, 23
X	Chemical Abstracts 120:49751 "New halogenated furanones from the marine alga <i>Delisea pulchra</i> (cf. <i>fimbriata</i>)", De Nys, R.; Wright Anthony D.; Konig, Gabriele, M.; Sticher Otto., Tetrahedron (1993) 49(48), 11213-20. See compounds disclosed RN: 63025-20-7, 63025-21-8, 63025-23-0, 63025-26-3, 63025-27-4, 63025-28-5, 63025-29-6, 63025-30-9, 63025-31-0, 63025-32-1, 63025-33-2, 63025-35-4, 63025-36-5	1-3, 17
X	Chemical Abstracts 117:111367 "Bromine addition to alpha-(1-hydroxyalkyl)-and alpha-(1-alkoxyalkyl)-alpha, beta-unsaturated esters: an approach to hydroxyfimbrolide and bromo beckerelide" See compound disclosed RN: 143140-80-1	1-3, 6-14, 17
X	Chemical Abstracts 103:6140 "A new Synthesis of 3-n-butyl-4-Bromo-5(z)-bromomethylidene-2(5H)-furanone, a naturally occurring fimbriolide from <i>Delisea fimbriata</i> ", Caine Drury; Ukachukwu, Victoria C., J. Org Chem (1985) 50(12), 2195-8 See compounds disclosed RN: 63025-35-4, 96129-51-0	1-3, 6-14, 17
X	Chemical Abstracts 99:139591 "Efficient Synthesis of acetoxymimbrolides and beckerelide analogs", Kotsuki Hiyoshizo; Monden Mitsugu; Ochi Masamitsu, Chem. Lett. (1983), (7), 1007-8 See compounds disclosed RN: 87241-09-6	1-3, 6-14, 17
X	Chemical Abstracts 91:192772 "The Synthesis of fimbrolides, a novel class of halogenated lactones occurring in the red seaweed <i>Delisea fimbriata</i> " Beechan Curtis M.; Sims James J., Tetrahedron Lett. (1979) (19), 1649-52 See compounds disclosed RN: 63025-34-3, 63025-35-4	1-3, 6-14, 17

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.
PCT/AU 99/00285

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
WO	99/05227	AU	8211/97				
WO	99/01514	AU	7720/97	AU	80943/98		
WO	96/01294	CN	1156471	AU	28750/95	CA	2192955
		EP	769039	JP	10502402	NZ	289025

16

PATENT COOPERATION TREATY
PCT
INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)


REC'D 24 MAY 2000

WIPO

PCT

Applicant's or agent's file reference 84411	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).
International application No. PCT/AU99/00285	International filing date (day/month/year) 16 April 1999	Priority Date (day/month/year) 16 April 1998
International Patent Classification (IPC) or national classification and IPC Int. Cl. ⁷ C07D 307/58, A61K 31/34, A01N 43/08, C08F 224/00, C23F 14/02, C23F 15/00		
Applicant UNISEARCH LIMITED et al		

1.	This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.																
2.	<p>This REPORT consists of a total of 4 sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of 11 sheet(s).</p>																
3.	<p>This report contains indications relating to the following items:</p> <table style="width: 100%;"> <tr> <td style="width: 5%;">I</td> <td><input checked="" type="checkbox"/> Basis of the report</td> </tr> <tr> <td>II</td> <td><input type="checkbox"/> Priority</td> </tr> <tr> <td>III</td> <td><input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</td> </tr> <tr> <td>IV</td> <td><input type="checkbox"/> Lack of unity of invention</td> </tr> <tr> <td>V</td> <td><input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</td> </tr> <tr> <td>VI</td> <td><input checked="" type="checkbox"/> Certain documents cited</td> </tr> <tr> <td>VII</td> <td><input type="checkbox"/> Certain defects in the international application</td> </tr> <tr> <td>VIII</td> <td><input type="checkbox"/> Certain observations on the international application</td> </tr> </table>	I	<input checked="" type="checkbox"/> Basis of the report	II	<input type="checkbox"/> Priority	III	<input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability	IV	<input type="checkbox"/> Lack of unity of invention	V	<input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement	VI	<input checked="" type="checkbox"/> Certain documents cited	VII	<input type="checkbox"/> Certain defects in the international application	VIII	<input type="checkbox"/> Certain observations on the international application
I	<input checked="" type="checkbox"/> Basis of the report																
II	<input type="checkbox"/> Priority																
III	<input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability																
IV	<input type="checkbox"/> Lack of unity of invention																
V	<input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement																
VI	<input checked="" type="checkbox"/> Certain documents cited																
VII	<input type="checkbox"/> Certain defects in the international application																
VIII	<input type="checkbox"/> Certain observations on the international application																

Date of submission of the demand 25 June 1999	Date of completion of the report 26 April 2000
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929	Authorized Officer  IAN DOWD Telephone No. (02) 6283 2273

I. Basis of the report**1. With regard to the elements of the international application:***

- ☐ the international application as originally filed.
- ☒ the description, pages **1, 3-24**, as originally filed,
pages , filed with the demand,
pages **2**, received on **21 December 1999** with the letter of **21 December 1999**
- ☒ the claims, pages , as originally filed,
pages , as amended (together with any statement) under Article 19,
pages , filed with the demand,
pages **25-34**, received on **21 December 1999** with the letter of **21 December 1999**
- ☒ the drawings, pages **1-5(I)**, as originally filed,
pages , filed with the demand,
pages , received on with the letter of
- ☐ the sequence listing part of the description:
pages , as originally filed
pages , filed with the demand
pages , received on with the letter of

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, was on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages
- ☐ the claims, Nos.
- ☐ the drawings, sheets/fig.

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. Statement**

Novelty (N)	Claims 4-20, 22, 24-26	YES
	Claims 1-3, 21, 23	NO
Inventive step (IS)	Claims 4-20, 22, 24-26	YES
	Claims 1-3, 21, 23	NO
Industrial applicability (IA)	Claims 1-26	YES
	Claims	NO

2. Citations and explanations (Rule 70.7)

The prior-art documents cited in the International Search Report were;

D1 Chemical Abstracts 130:155029
D2 Chemical Abstracts 130:111094
D3 Chemical Abstracts 128:241398
D4 Chemical Abstracts 124:234956
D5 Chemical Abstracts 120:49751
D6 Chemical Abstracts 117:111367
D7 Chemical Abstracts 103:6140
D8 Chemical Abstracts 99:139591
D9 Chemical Abstracts 91:192772

Chemical Abstract D2 (above) discloses compound (RN 219640-53-6) that falls within the scope of claims 1-3. The compound discloses R6 = Me, R2 = H, R3, R9 and Z = Br. This compound is not excluded by the provisos. Use as an anti-fouling agent is also disclosed.

Thus, claims 1-3, 21 and 23 are not novel and lacks inventive step in the light of D2.

The compounds of citations **D1** and **D2** of Box VI and **Chemical Abstracts D1** and **D3** to **D9** (cited above) are excluded by the proviso of claims 1-3. Compounds claimed in claims 4-5 are not disclosed in the above prior art.

The process disclosed by **D6** involves producing fimbrolides via ionic bromination of olefins in which the starting compounds are not furanones. Therefore, claims 1-3 and 6-14 are novel and involve inventive step over **D6**.

D7 represents the closest art for the methods of present claims 6 and 9. However, claim 6 requires that substituent X be halogen, OH, OOH, OC(O)R1 or =O, whereas the equivalent position in **D7** is H. Similarly for claim 9 and its R4 group.

The processes disclosed by **D8** and **D9** do not use fimbrolide starting compounds. Thus claims 6-14 are novel and involve inventive step in the light of **D8** and **D9**.

With regard to citations **D1** and **D2** (see Box VI), claims 18 and 20 and 23 are novel and involve an inventive step since the prior art teaches a blend of an antifouling agent with a polymer, whereas the claims in question form a polymer or oligomer using the given compounds.

Therefore the claims are novel and involve an inventive step with regard to the above prior art.

VI. Certain documents cited**1. Certain published documents (Rule 70.10)**

	Application No. Patent No.	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
D1	WO 99/05227	4 February 1999	3 July 1998	24 July 1997
D2	WO 99/01514	14 January 1999	3 July 1998	4 July 1997


While **D1** has a later publication date than the priority date of the present application, the compounds disclosed and the anti-fouling composition were also disclosed in citations published before said priority date (cf. Citations **D3**, **D5** and **D9**).

An examination of the priority document revealed that the compounds of claim 5 are not entitled to the earliest priority date claimed. Similarly, not all of the compounds claimed in claims 1-4 are entitled to the earliest priority date claimed.

2. Non-written disclosures (Rule 70.9)

Kind of non-written disclosure	Date of non-written disclosure (day/month/year)	Date of written disclosure referring to non-written disclosure (day/month/year)
--------------------------------	--	---

novel compounds. The compounds synthesised in accordance with the present invention may be according to formula (I):



(I)

wherein R_6 is H, OH, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

R_2 and R_3 are independently or both H or halogen;

R_9 is halogen;

Z is independently selected from the group R_6 , halogen, OOH, $OC(O)R_6$, = O, amine, azide, thiol, R_6 , mercaptoalkyl, alkenyloxy, mercaptoalkenyl, aryloxy, mercaptoaryl, arylalkyloxy, mercaptoarylalkyl, $SC(O)R_6$, $OS(O)R_6$, $OS(O)_2R_6$, $NHC(O)R_6 = NR_4$ or NHR_4 ; and

R_4 is OH, alkyl, alkoxy, poly(ethylene glycol), alkenyl, aryl or arylalkyl.

Compounds according to Formula (I), apart from those in which R_1 = propyl, R_2 = Br, R_3 = H, R_9 = Br and Z is $OC(O)CH_3$ or OH, are believed to be novel and form part of the present invention.


Disclosure of Invention

In a first aspect, the present invention provides a method to form a fimbrolide derivative, the method including reacting a fimbrolide with a halogenating agent and/or an oxygenating agent to form compounds with formula (Ia):

Replaced by 47734

CLAIMS:

1. A compound according to formula (I):



(I)

wherein R_6 is H, OH, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;


R_2 and R_3 are independently or both H or halogen;

R_9 is halogen;

Z is independently selected from the group R_6 , halogen, OOH, $OC(O)R_6$, = O, amine, azide, thiol, R_6 , mercaptoalkyl, alkenyloxy, mercaptoalkenyl, aryloxy, mercaptoaryl, arylalkyloxy, mercaptoarylalkyl, $SC(O)R_6$, $OS(O)R_6$, $OS(O)_2R_6$, $NHC(O)R_6 = NR_4$ or NHR_4 ; and

R_4 is OH, alkyl, alkoxy, poly(ethylene glycol), alkenyl, aryl or arylalkyl. provided that when R_1 is propyl, R_2 is Br, R_3 is H, R_9 is Br, Z is other than $OC(O)CH_3$ or OH.

2. A compound according to claim 1 of formula (Ia):



(Ia)


wherein R_1 is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

X is a halogen, OH, OOH, $OC(O)R_1$ or $=O$;

R_2 and R_3 are independently or both hydrogen or halogen; and

R_9 is halogen, provided that when R_1 is propyl, R_2 is Br, R_3 is H and R_9 is Br, Y is other than $OC(O)CH_3$ or OH.

3. A compound according to claim 1 of formula (II):



(II)


wherein R_1 is hydrogen, unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl;

R_2 and R_3 are independently or both hydrogen or halogen;

R_9 is halogen; and

R_4 is selected from the group halogen, amine, azide, hydroxyl, thiol, or any hydrophobic, hydrophilic or fluorophilic alkyl, alkoxy, mercaptoalkyl, alkenyloxy, mercaptoalkenyl, aryloxy, mercaptoaryl, arylalkyloxy, mercaptoarylalkyl, $OC(O)R_1$, $SC(O)R_1$, $OS(O)R_1$, $OS(O)_2R_1$, $NHC(O)R_1$, $OC(O)NHR_1$, or $=O$, provided that when R_1 is propyl, R_2 is Br, R_3 is H, and R_9 is Br, R_4 is other than $OC(O)CH_3$ or OH.

4. A compound according to claim 1 of formula (III):



(III)


wherein R_2 and R_3 are independently or both hydrogen or halogen;

R_5 is OH or the same as R_1 ;


R_9 is halogen; and

R_1 is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic.

5. A compound according to claim 1 of formula (IV) or (V):



(IV)



(V)


wherein R_1 is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

R_2 and R_3 are independently or both hydrogen or halogen;

R_9 is halogen and

R_8 is OH, NHR_1 , $NHC(X)NH_2$, $NHC(X)NHR_1$ ($X=O, S, NR_1$) or any R_1 .

6. A method for forming a fimbrolide derivative, the method including reacting a fimbrolide with a halogenating agent and/or an oxygenating agent to form compounds with formula (Ia):



(Ia)

wherein R₁ is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

X is a halogen (X = F, Cl, Br or I), OH, OOH, OC(O)R₁ or =O);


R₂ and R₃ are independently or both hydrogen or halogen; and

R₉ is halogen.

7. A method according to claim 6 wherein the halogenating agent is selected from the group N-bromosuccinimide, N-chlorosuccinimide, N-iodosuccinimide, bromine, cupric bromide, and phenyltrimethylammonium perbromide.

8. A method according to claim 6 wherein the oxygenating agent is selected from lead tetraacetate, Rose Bengal/oxygen gas, hydrogen peroxide/vanadium pentoxide, selenium dioxide, and 3-chloroperoxybenzoic acid.

9. A method for forming a fimbrolide derivative, the method including displacement and/or functionalisation of the halogen or oxygen substituent in the fimbrolide side chain by treating with a nucleophile or an electrophile to form compounds with formula (II):



(II)

wherein R_1 is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

R_2 and R_3 are independently or both hydrogen or halogen;


R_9 is halogen; and

R_4 is selected from the group halogen, amine, azide, hydroxyl, thiol, or any hydrophobic, hydrophilic or fluorophilic alkyl, alkoxy, mercaptoalkyl, alkenyloxy, mercaptoalkenyl, aryloxy, mercaptoaryl, arylalkyloxy, mercaptoarylalkyl, $OC(O)R_1$, $SC(O)R_1$, $OS(O)R_1$, $OS(O)_2R_1$, $NHC(O)R_1$, $OC(O)NHR_1$, or $=O$.

10. A method according to claim 9 wherein the nucleophile is selected from metal halides, water, organic metal carboxylate, organic alcohols, dimethyl sulfoxide, and organonitrile/acid catalyst, and silver triflate.

11. A method according to claim 9 wherein the electrophile is selected from organic acids, isocyanates, acid halides or active acylating agents such as carbonyl imidazoles or anhydrides (including activated hydrophilic PEG acids, PEG acid chlorides, PEG-oxycarbonylimidazoles and PEG-isocyanates) organic sulfonyl chlorides, and diethylaminosulfur trifluoride.

12. A method for forming a fimbrolide derivative the method including reacting an hydroxyl substituent in the fimbrolide side chain with an oxidising agent to form a compound in accordance with formula (III):



wherein R₂ and R₃ are independently or both hydrogen or halogen;

R₅ is OH or the same as R₁;


R₉ is halogen; and

R₁ is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic.

13. A method according to claim 12 wherein the oxidising agents is selected from the group consisting of acid dichromate reagents in any form which may be free or polymer supported, chromium trioxide, manganese dioxide, potassium permanganate, selenium dioxide, ceric ammonium nitrate, ruthenium tetroxide, and hot nitric acid.

14. A method according to claim 13 wherein the acid dichromate agent is selected from the group consisting of Jones reagent, pyridinium chlorochromate, pyridinium dichromate.

15. A method for forming a fimbrolide analogue derived from a compound of formula (III)




wherein R₂ and R₃ are independently or both hydrogen or halogen;

R₅ is OH or the same as R₁;


R₆ is halogen; and

R₁ is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic,

the method including reacting an aldehyde or ketone substituent in the fimbrolide side chain of the compound with an amine derivative to form a compound with formula (IV) or (V):



(IV)



(V)

wherein R₁ is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

R₂ and R₃ are independently or both hydrogen or halogen;


R₆ is halogen and

R₈ is OH, NHR₁, NHC(X)NH₂, NHC(X)NHR₁ (X=O, S, NR₁) or any R₁.

16. A method according to claim 15 wherein the amine derivative is selected from the group hydroxyl amine hydrochloride, alkyl and aryl hydrazines, alkyl or aryl amine optionally in the presence of a reducing agent.

17. A fimbrolide derivative produced by a method in accordance with any one of claims 6 to 16.

18. An oligomer or polymer derived from a compound in accordance with any one of claims 1 to 5 or 17.
19. A polymer according to claim 18 wherein the polymer is a homopolymer.
20. A polymer according to claim 18 wherein the polymer is a copolymer of at least one compound in accordance with any one of claims 1 to 5 or 17 and one or other polymerisable monomers.
21. Use of a compound in accordance with any one of claims 1 to 5 or 17 as antimicrobial, antiseptic, microbacterial static and/or antifouling agent.
22. An antimicrobial, antiseptic and/or microbacterial static composition including at least one compound in accordance with claims 1 to 5 or 17, or an oligomer or polymer according to any one of claims claims 18 to 20.
23. An antifouling composition including at least one compound in accordance with claims 1 to 5 or 17, or an oligomer or polymer according to any one of claims claims 18 to 20.
24. A surface coating composition incorporating at least one compound according to any one of claims 1 to 5 or 17 or an oligomer or polymer according to any one of claims 18 to 20.
25. A compound of formula (VI):



(VI)

wherein R₁ is alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

R₂ and R₃ are independently or both hydrogen or halogen; and
R₉ is halogen.

26. A compound according to claim 25 which is 4-Bromo-5-(bromomethylene)-3-(1-butenyl)-2(5H)-furanone.

WO 99/54323

14/PRTS

PCT/AU99/00285

09/673305
529 Rec'd PCT/PTO 16 OCT 2000

1

Production of furanones

Technical Field

The present invention relates to the side chain functionalisation of fimbrolides (halogenated 3-alkyl-5-methylene-2(5H)-furanones) and their synthetic analogues, that yields fimbrolides substituted with a halogen, an oxygen or a nitrogen functionality in the alkyl chain, especially fimbrolide alcohols, carboxylate and sulfinate and sulfonate esters, ethers, aldehydes, ketones, acids, amides, nitro derivatives, and polymers.

Background Art

It is known that a variety of fimbrolides possessing antifungal and antimicrobial properties can be isolated from red marine algae *Delisea fimbriata*, *Delisea elegans* and *Delisea pulchra*. The very few reported syntheses of functionalised fimbrolides use (E)- β -bromo- β -lithioacrylate or 3-formyl-6-methylfuran or allenes as starting materials. These syntheses are unnecessarily long, tedious and give very low yields of the fimbrolides. The present inventors have recently reported the preparation of a range of fimbrolides having different sized chain lengths (Manny et al (1997) Tetrahedron 53: 15813-15826, the disclosure of which is incorporated herein by reference).


Prior to the present invention, it had not been appreciated that the side chains of the fimbrolides could be functionalised directly affording a variety of halogen or oxygen functionalised fimbrolides. We have found that fimbrolides behave like allylic or benzylic compounds in their reactivity and consequently are amenable to free radical functionalisation. The derived halogen compounds can be converted to alcohols or to esters directly from the halogen derivatives or to ketones, esters, amides, alcohols or other halides indirectly from the corresponding esters or alcohols. The fimbrolides substituted with an appropriate group in the alkyl chain are capable of yielding polymers through that group, either directly or via copolymerisation with suitable monomers. It is the preparation of these fimbrolide-based halides, alcohols, esters, ethers, amines, amides, and nitro compounds, ketones, oligomers and polymers that form the major aspect of this invention.

The fimbrolides prepared in accordance with the present invention include not only synthetic versions of the two naturally occurring fimbrolides, but also other functionalised fimbrolides which we believe to be

Article 34
2/12/99

2

novel compounds. The compounds synthesised in accordance with the present invention may be according to formula (I):



(I)

wherein R_6 is H, OH, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

R_2 and R_3 are independently or both H or halogen;

R_9 is halogen;

Z is independently selected from the group R_6 , halogen, OOH, $OC(O)R_6$, = O, amine, azide, thiol, R_6 , mercaptoalkyl, alkenyloxy, mercaptoalkenyl, aryloxy, mercaptoaryl, arylalkyloxy, mercaptoarylalkyl, $SC(O)R_6$, $OS(O)R_6$, $OS(O)_2R_6$, $NHC(O)R_6 = NR_4$ or NHR_4 ; and R_4 is OH, alkyl, alkoxy, poly(ethylene glycol), alkenyl, aryl or arylalkyl.

Compounds according to Formula (I), apart from those in which R_1 = propyl, R_2 = Br, R_3 = H, R_9 = Br and Z is $OC(O)CH_3$ or OH, are believed to be novel and form part of the present invention.

In the structural formulae given herein, a particular geometry is not to be taken as specified unless specifically stated. For example, the formulae are intended to cover the both Z-isomers and E-isomers.


Disclosure of Invention

In a first aspect, the present invention provides a method to form a fimbrolide derivative, the method including reacting a fimbrolide with a halogenating agent and/or an oxygenating agent to form compounds with formula (Ia):

WO 99/54323

PCT/AU99/00285

3



(Ia)


wherein R₁ is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl, whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

X is a halogen (X = F, Cl, Br or I), OH, OOH, OC(O)R₁ or =O);

R₂ and R₃ are independently or both hydrogen or halogen; and

R₉ is halogen.

The fimbrolide used in the method may be a fimbrolide having the formula:



wherein R₁, R₂, R₃ and R₉ are as defined above.

Preferably the halogenating agent is selected from N-bromosuccinimide, N-chlorosuccinimide, N-iodosuccinimide, bromine, cupric bromide, and phenyltrimethylammonium perbromide. It will be appreciated, however, that other halogenating agents would also be suitable for the present invention.

Preferably the oxygenating agent is selected from lead tetraacetate, Rose Bengal/oxygen gas, hydrogen peroxide/vanadium pentoxide, selenium dioxide, and 3-chloroperoxybenzoic acid. It will be appreciated, however, that other oxygenating agents would also be suitable for the present invention.

The reaction conditions are selected so as to be appropriate to the nature of the reaction being undertaken. Preferably, the reaction conditions

WO 99/54323

PCT/AU99/00285

4


when an halogenating agent is used are for example carbon tetrachloride or chloroform or dichloromethane/with or without light/reflux, tetrahydrofuran/room temperature.

Preferably, the reaction conditions when an oxygenating agent is used are acetic acid or acetic acid mixed with a solvent/reflux, pyridine/room temperature, acetone/30°C, dioxane/reflux, and dichloromethane/room temperature.

The present inventors have found that the preferred bromination conditions are N-bromosuccinimide in the presence of catalytic amounts of benzoyl peroxide in carbon tetrachloride and light/reflux. The source of light may be any suitable source for example, the present inventors have found that a 250 W sun lamp is quite suitable.

In a second aspect, the present invention consists in a fimbrolide derivative having formula (Ia), wherein R₁ is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic; X is a halogen (X = Cl, Br or I) or oxygen (X = OH, OOH, OC(O)R₁ or =O); R₂, R₃ are independently or both hydrogen or halogen and; R₄ is halogen, with the proviso that the following two derivatives are excluded R₁ = propyl, X = OH, R₂ = Br, R₃ = H; and R₁ = propyl, X = OC(O)CH₃, R₂ = Br, R₃ = H).

In a third aspect, the present invention consists of a method to form a fimbrolide derivative, the method including displacement and/or functionalisation of the halogen or oxygen substituent in the fimbrolide side chain by treating with a nucleophile or an electrophile to form compounds with formula (II):



(II)

wherein R₁ is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl, whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

WO 99/54323

PCT/AU99/00285


5

R_2 and R_3 are independently or both hydrogen or halogen;

R_5 is halogen; and

R_4 is selected from the group halogen, amine, azide, hydroxyl, thiol, or any hydrophobic, hydrophilic or fluorophilic alkyl, alkoxy, mercaptoalkyl, alkenyloxy, mercaptoalkenyl, aryloxy, mercaptoaryl, arylalkyloxy, mercaptoarylalkyl, $OC(O)R_1$, $SC(O)R_1$, $OS(O)R_1$, $OS(O)_2R_1$, $NHC(O)R_1$, $OC(O)NHR_1$, or $=O$.

The fimbrolide treated in the method of the third aspect may be compound of the formula:



wherein R_1, R_2, R_3 and R_5 are as defined above and R_7 is halogen (F, Cl, Br or I), OH, OOH, $OC(O)R_1$ or $=O$);

Preferably the nucleophile is selected from metal halides, water, organic metal carboxylates, organic alcohols, dimethyl sulfoxide, and organonitriles. It will be appreciated, however, that other nucleophiles would also be suitable for the present invention.

Preferably the electrophile is selected from organic acids, isocyanates, carboxylic or sulfonic acid halides or active acylating or sulfinylating agents such as carbonyl imidazoles, carboxylic anhydrides, carbodiimide activated carboxylic acids, sulfonyl halides, and sulfonic anhydrides and diethylaminosulfur trifluoride. It will be appreciated, however, that other electrophiles would also be suitable for the present invention.

The reaction conditions of the method of the third aspect are selected to be appropriate to the nature of the reaction being undertaken.

The reaction conditions suitable when using a nucleophile are acetone or dioxane/room temperature or reflux, water/dioxane or acetone or tetrahydrofuran/reflux, metal acetates/organic acids/neat or high boiling solvents/reflux, organic alcohols/reflux, dimethyl sulfoxide/room temperature, and organonitriles/acid catalyst or silver triflate/reflux.

WO 99/54323


PCT/AU99/00285

6

The reaction conditions suitable when using an electrophile are organic acids/neat and/or solvent/acid catalyst/reflux, organic acid halides or anhydrides or isocyanates /base catalyst/solvent/room temperature, and diethylaminosulfur trifluoride/dichloromethane/low temperature.

In a fourth aspect the present invention consists in a fimbrolide derivative having formula (II), wherein R_1 is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic; R_2 and R_3 are independently or both hydrogen or halogen; R_4 is halogen, and R_4 is selected from the group halogen, amine, azide, hydroxyl, thiol, or any hydrophobic, hydrophilic or fluorophilic alkyl, alkoxy, mercaptoalkyl, alkenyloxy, mercaptoalkenyl, aryloxy, mercaptoaryl, arylalkyloxy, mercaptoarylalkyl, $OC(O)R_1$, $SC(O)R_1$, $OS(O)R_1$, $OS(O)_2R_1$, $NHC(O)R_1$, $OC(O)NHR_1$, or $=O$, with the proviso that the following two derivatives are excluded $R_1 = \text{propyl}$, $X = OH$, $R_2 = Br$, $R_3 = H$; 2. $R_1 = \text{propyl}$, $X = OC(O)CH_3$, $R_2 = Br$, $R_3 = H$.

In a fifth aspect, the present invention consists of a method to form a fimbrolide derivative the method including reacting an hydroxyl substituent in the fimbrolide side chain with an oxidising agent to form a compound in accordance with formula (III):



(III)

wherein R_2 and R_3 are independently or both hydrogen or halogen;

R_5 is OH or the same as R_1 ;

R_4 is halogen; and


R_1 is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic.

WO 99/54323

PCT/AU99/00285

7

The hydroxyl substituted fimbrolide used in the method of the fifth aspect may have the formula:



wherein R_5 , R_2 and R_1 are as defined above.

Preferably, the oxidising agents are acidic chromium reagents in any form either free or polymer supported (e.g. Jones reagent, pyridinium chlorochromate, pyridinium dichromate, chromium trioxide etc), manganese dioxide, potassium permanganate, selenium dioxide, ceric ammonium nitrate, ruthenium tetroxide, and hot nitric acid. It will be appreciated, however, that other oxidation agents may also be used for the present invention.

The reaction condition under which the method of the third aspect is performed may be any suitable conditions. The reaction conditions preferably use Jones reagent/with or without phase transfer catalysts/acetone/room temperature, toluene/reflux, potassium permanganate/buffered solution/room temperature, dioxane/reflux, ceric ammonium nitrate/ aqueous acetic acid/steam bath, carbon tetrachloride/reflux, and acetic acid/steam bath. It will be appreciated, however, that other reaction conditions may also be used for the present invention.

The present inventors have found that the use of Jones reagent in acetone/room temperature is particularly suitable.

In a sixth aspect, the present invention consists in a fimbrolide derivative having the formula (III) wherein R_1 is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic; R_2 and R_3 are independently or both hydrogen or halogen; R_9 is halogen; and R_5 is OH or the same as R_1 .


The present invention also provides a method for forming fimbrolide oximes, imines, hydrazones and amines.

WO 99/54323


PCT/AU99/00285

8

Accordingly in a seventh aspect, the present invention consists of a method to form a fimbrolide analogue derived from a compound of formula (III), the method including reacting an aldehyde or ketone substituent in the fimbrolide side chain of the compound with an amine derivative to form a compound with formula (IV) or (V):



(IV)



(V)

wherein R_1 is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

R_2 and R_3 are independently or both hydrogen or halogen;

R_9 is halogen and

R_8 is OH, NHR_1 , $NHC(X)NH_2$, $NHC(X)NHR_1$ ($X = C, S, NR_1$) or any R_1 .

Preferably, the amine derivatives used are hydroxyl amine hydrochloride, alkyl and aryl hydrazines, alkyl or aryl amine in the presence or absence of a reducing agent. It will be appreciated, however, that other amine derivatives may also be used for the present invention.

The reaction conditions used in the method of the seventh aspect may be any conditions suitable for the nature of the reaction carried out. For example when using an amine derivative suitable conditions are ethanol or methanol/room temperature or reflux, toluene in the presence of a catalyst/room temperature or reflux and ethanol or methanol in the presence of sodium borohydride or sodium cyanoborohydride/room temperature or reflux.

In a eighth aspect, the present invention consists in a fimbrolide derivative having the formula (IV) and (V) wherein R_1 is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or

WO 99/54323

PCT/AU99/00285

9

fluorophilic; R_2 and R_3 are independently or both hydrogen or halogen, R_9 is halogen and R_8 is OH, NHR_1 , $NHC(X)NH_2$, $NHC(X)NHR_1$ ($X=O, S, NR_1$) or any R_1 .

In a ninth aspect the present invention provides an oligomer or polymer formed by oligomerising or polymerising a compound in accordance with the present invention directly or with one or more other monomers.


The one or more other monomer may be any suitable polymerisable copolymer eg acrylate ester such as alkyl, hydroxyalkyl, aminoalkyl, or substituted aryl, acrylates or methacrylates, crotonates, substituted or unsubstituted acrylonitriles, vinyl alcohols or acetates, and styrene.

In a tenth aspect, the present invention consists in incorporation of fimbrolides according to the first, third, fifth or seventh aspects of the present invention either in surface coatings or polymers through the newly introduced functionality on the alkyl chain or the alkyl chain itself via direct polymerisation or copolymerisation with suitable monomers.

In a eleventh aspect, the present invention consists in a fimbrolide derivative produced by the method according to the first, third, fifth or seventh aspects of the present invention.

In an twelfth aspect, the present invention consists in the use of a fimbrolide derivative according to the present invention. The present inventors have found that many of the fimbrolide derivatives having the formula (I), have antimicrobial, antiseptic, microbacterial static and/or antifouling properties. Accordingly, the fimbrolide derivatives are suitable for use as antimicrobial and/or antifouling agents.

In a thirteenth aspect the present invention provides a compound of formula (VI):



(VI)

wherein R_2 , R_3 , R_9 and R_1 (except where R_1 is hydrogen) are as defined above.

WO 99/54323

PCT/AU99/00285

10

An example of a compound in accordance with this form of the invention is 4-Bromo-5-(bromomethylene)-3-(1-butenyl)-2(5H)-furanone.

The compound of the thirteenth aspect may be formed by dehydrating hydroxyl substituent in the fimbrolide side chain. The dehydration may be catalysed by H₂SO₄ in the presence of toluene.

As used herein and in the claims:

The term "halogen" means F, Cl, Br, or I.

The term "alkyl" is taken to mean straight chain, branched chain and cyclic alkyl or cycloalkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, cyclopentyl, hexyl, cyclohexyl, and the like. Preferably the alkyl group is of 1-25 carbon atoms. The alkyl group may be optionally substituted by one or more of fluorine, chlorine, bromine, iodine, carboxyl, C1-C4-alkoxycarbonyl, hydroxyl, carbonyl and aryl groups.

The term "aryl" is taken to include substituted and unsubstituted phenyl, naphthyl or other benzenoid aromatic or any aromatic heterocyclic nucleus containing N, O, S, P or chalcogen heteroatom such as pyridyl, pyrimidyl, indolyl or furanyl.

The term "alkoxy" as used herein and in the claims denotes straight chain or branched alkoxy, preferably containing 1 to 25 carbon atoms and like functional groups, such as polyethylene glycol (PEG) and cyclic ethers.

The term "alkenyl" is taken to mean a straight chain, a branched chain or cycloalkyl group having one or more double bonds. Preferably the alkyl group is 1-25 carbon atoms. The alkyl group may optionally be substituted by one or more halogen atoms, carbonyl, hydroxyl, carboxyl, C1-C4-alkoxycarbonyl groups.

The term "amine" as used herein and in the claim means any basic primary, secondary or tertiary nitrogen containing group or molecule, aromatic or non-aromatic.

WO 99/54323

PCT/AU99/00285

11

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or step, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

In order that the present invention may be more clearly understood, preferred forms will be described with reference to the following examples and accompanying drawings.

Brief Description of Drawings

Figure 1 shows the structure of *Delisea pulchra* furanones and synthetic analogues and derivatives tested in barnacle settlement assay.

Figure 2 shows the effect of furanones 2, 281, 2223, 2425, 26, 27, and 28 on the settlement of barnacle cyprid larvae as measured by settlement expressed as a percent of the control.

Figure 3 shows growth curves of *Staphylococcus aureus* against different furanones.

Figure 4 shows growth curves of *Staphylococcus aureus* against compounds 33/34 and 45.

Figures 5-51 show the structural formulae for other specific examples of compounds in accordance with the present invention.

Modes for Carrying Out the Invention

EXPERIMENTAL DETAILS

Fimbrilide Production

General. Melting points are uncorrected. Microanalyses were performed by Dr H.P. Pham of The University of New South Wales Microanalytical Laboratory. ¹H NMR spectra were obtained in CDCl₃ on a Bruker AC300F (300 MHz) or a Bruker DMX500 (500 MHz) spectrometer. ¹³C NMR were obtained in the same solvent on a Bruker AC300F (75.5 MHz) or a Bruker DMX500 (125.8 MHz) spectrometer. Chemical shifts were measured on the δ scale internally referenced to the solvent peaks: CDCl₃ (d 7.26, d 77.04). Ultraviolet spectra were measured on an Hitachi U-3200 spectrophotometer and refer to solutions in absolute MeOH. Infrared spectra were recorded on a Perkin-Elmer 298 or a Perkin-Elmer 580B spectrophotometer and refer to paraffin mulls. The electron impact mass spectra were recorded on a VG Quattro mass spectrometer at 70eV ionisation

WO 99/54323

PCT/AU99/00285

12

voltage and 200°C ion source temperature. FAB spectra were recorded on an AutoSpecQ mass spectrometer. Column chromatography was carried out using Merck silica gel 60H (Art. 7736), whilst preparative thin layer chromatography was performed on 2 mm plates using Merck silica gel 60GF254 (Art. 7730).

RESULTS

Fimbrilide Production

Examples of a number of fimbrilides produced are provided below.

EXAMPLE 1

4-Bromo-5-(bromomethylene)- and 5-(dibromomethylene)-3-(1-bromoethyl)-2(5H)-furanone

N-bromosuccinimide (17.3 g, 0.097 mol) was added to a solution of 4-bromo-5-(bromomethylene)- and/or 5-(dibromomethylene)-3-ethyl-2(3H)-furanone (22.6 g, 0.08 mol) in carbon tetrachloride (500 ml) containing benzoyl peroxide (0.25 g). The mixture was irradiated with a 250 W lamp and refluxed in an oil bath for 18h. After cooling the mixture to room temperature it was filtered and the precipitate washed with carbon tetrachloride (50 ml). The filtrate was evaporated under reduced pressure and the crude product was purified by silica gel chromatography using dichloromethane / light petroleum (2 : 3) as the eluent to yield the bromo compounds (22.0 g, 76%) as a 4 : 1 mixture.

4-Bromo-5-(bromomethylene)-3-(1-bromoethyl)-2(5H)-furanone

A pale yellow solid, m.p. 79°C. ν_{\max} 2850, 1750, 1630, 1580, 1440, 1360, 1270, 1180, 1065, 1000, 970, 940, 1080, 755 cm^{-1} . λ_{\max} 306 nm (e 10826). ^1H n.m.r. δ (CDCl_3) 2.06, d, J 7.2 Hz, (H_2')₃; 5.00, q, J 7.2 Hz, H_1' ; 6.45, s, 5-CHBr. ^{13}C n.m.r. δ (CDCl_3): 22.3, C_2' ; 35.7, C_1' ; 94.3, 5-CHBr; 130.5, C_4 ; 133.7, C; 149.5, C_5 ; 165.8, C2. Mass spectrum: m/z 364 (M ($^{81}\text{Br}_3$), 2%); 362 (M ($^{81}\text{Br}_2$, ^{79}Br), 8); 360 (M (^{81}Br , $^{79}\text{Br}_2$), 8); 358 (M ($^{79}\text{Br}_3$), 2); 283 (85); 281 (100); 279 (85); 202 (12); 200 (12); 173 (18); 153 (35); 156 (35); 145 (38); 143 (42); 133 (28); 121 (26).

5-(Dibromomethylene)-3-(1-bromoethyl)-2(5H)-furanone

A white solid m.p. 119°C. ν_{\max} 2900, 1720, 1590, 1450, 1370, 1250, 1170, 1080, 1060, 1000, 960, 840, 770, 720 cm^{-1} . λ_{\max} 319 nm (e 12225). ^1H n.m.r. δ (CDCl_3): 1.99, t, J 7.2 Hz, (H_2')₃; 4.87, q, J 7.2 Hz, H_1' ; 7.56, s, H_4 . ^{13}C n.m.r. δ (CDCl_3): 23.9, C_2' ; 36.0, C_1' ; 82.8, (5- CBr_2); 134.7, C_4 ; 138.2, C_3 ; 149., C_5 ; 165.5, C2. Mass spectrum: m/z 364 (M ($^{81}\text{Br}_3$), 9%); 362 (M ($^{81}\text{Br}_2$,

PCT/AU99/00285

WO 99/54323

13

⁷⁹Br), 18); 360 (M (⁸¹Br ⁷⁹Br₂), 18); 358 (M (⁷⁹Br₃), 9); 283 (78); 281 (100); 279 (78); 227 (8); 225 (12); 223 (8); 202 (22); 200 (32); 174 (18); 172 (44); 146 (42); 145 (50); 144 (50); 143 (60).

EXAMPLE 2**3-(1-Bromobutyl)-5-(dibromomethylene)-2(5H)-furanone**

The procedure described for 4-bromo-5-(bromomethylene)- and 5-(dibromomethylene)-3-(1-bromomethyl)-2(5H)-furanone was used to treat 3-butyl-5-(dibromomethylene)-2(5H)-furanone (4.95g, 16 mmol) with N-bromosuccinimide (3.83g, 22 mmol) in carbon tetrachloride (70 ml) to give after chromatography the bromobutyl furanone as a yellow solid (5.48g, 88%) m.p. 55°C. ν_{\max} 3087, 2924, 2854, 1778, 1463, 1377, 967, 832 cm⁻¹. λ_{\max} 314.2 nm (e 28115). ¹H NMR δ : 0.99 t, 3H, H-4'; 1.50 m, 2H, H-3'; 2.10 m, 2H, H-2'; 4.72 t, 1H, H-1'; 7.54 s, 1H, H4. Mass spectrum: m/z 392 (M+1(⁸¹Br₃); 389(M+1(⁸¹Br, ⁷⁹Br₂); 386(M+1(⁷⁹Br₃); 311; 309; 307; 289; 267 (100%); 265.

EXAMPLE 3**4-Bromo-5-(bromomethylene)- and 5-(dibromomethylene)- 3-(1-acetoxybutyl)-2(5H)-furanone**

A solution of 4-bromo-5-(bromomethylene)- and/or 5-(dibromomethylene)- 3-(1-bromobutyl)-2(5H)-furanone (3.00 g, 7.7 mmol) in glacial acetic acid (160 ml) containing sodium acetate (1.20 g, 15 mmol) was refluxed for 18h. The mixture was concentrated to approximately 20 ml and neutralised with excess saturated sodium carbonate solution. The residual oil was extracted with ether (3 x 100 ml), washed with brine, dried over sodium sulfate and evaporated. The crude product was chromatographed on silica gel using dichloromethane / light petroleum (1 : 1) as eluent to yield the acetoxybutylfuranones (0.96 g, 34%) as a 4 : 1 mixture.

4-Bromo-5-(bromomethylene)-3-(1-acetoxybutyl)-2(5H)-furanone

A pale yellow oil ν_{\max} 2940, 1775, 1740, 1640, 1600, 1450, 1420, 1370, 1220, 1100, 1020, 985, 760, 730 cm⁻¹. λ_{\max} 295 nm (e 6265). ¹H n.m.r. δ (CDCl₃) 0.93, t, J 7.2 Hz, (H4')₃; 1.35, m, (H3')₂; 1.84, m, (H2')₂; 2.07, s, COCH₃; 5.50, bt, J 7.2 Hz, H1'; 6.37, s, 5-CHBr. ¹³C n.m.r. δ (CDCl₃): 13.5, C4'; 18.5, COCH₃; 20.6, C3'; 33.7, C2'; 68.2, C1'; 93.5, 5-CHBr; 130.2, C4; 131.4, C3; 149.7, C5; 164.2, C2; 170.2, CO. Mass spectrum: m/z 370, (M (⁸¹Br₂), <5%); 368 (M (⁸¹Br, ⁷⁹Br), <5); 366, (M (⁷⁹Br₂), <5); 327 (18); 325

WO 99/54323

PCT/AU99/00285

14

(26); 323 (18); 289 (22); 287 (22); 285 (14); 283 (28); 281 (14); 247 (12); 245 (12); 229 (14); 227 (14); 149 (28).

5-(Dibromomethylene)-3-(1-acetoxybutyl)-2(5H)-furanone

A pale yellow solid mp 76°C. ν_{\max} 2880, 1760, 1735, 1445, 1370, 1225, 1170, 1100, 1030, 950, 840, 765, 7320 cm^{-1} . λ_{\max} 314 nm (e 8900). ^1H n.m.r. δ (CDCl_3) 0.94, t, J 7.2 Hz, (H_4')₃; 1.36, m, (H_3')₂; 1.84, m, (H_2')₂; 2.12, s, COCH_3 ; 5.59, bt, J 6.2 Hz, H_1' ; 7.39, bs, H_4 . ^{13}C n.m.r. δ (CDCl_3): 13.6, C_4' ; 18.3, COCH_3 ; 20.9, C_3' ; 34.8, C_2' ; 68.3, C_1' ; 81.6, 5- CBr_2 ; 135.0, C_4 ; 136.1, C_3 ; 149.3, C_5 ; 166.1, C_2 ; 169.9, CO. Mass spectrum: m/z 370, (M ($^{81}\text{Br}_2$), 28%); 368 (M (^{81}Br , ^{79}Br), 54); 366, (M ($^{79}\text{Br}_2$), 28); 328 (20); 327 (18); 326 (36); 325 (28); 324 (20); 323 (18); 289 (18); 287 (16); 247 (16); 245 (16); 229 (12); 227 (12); 198 (10).

EXAMPLE 4

5-(Dibromomethylene)-3-(1-acetoxyethyl)-2(5H)-furanone

The procedure described for 4-bromo-5-(bromomethylene)-3-(1-acetoxybutyl)-2(5H)-furanone was used to treat 5-(dibromomethylene)-3-(1-bromoethyl)-2(5H)-furanone (2.80 g, 7.7 mmol) with sodium acetate (1.20 g, 15 mmol) in glacial acetic acid (160 ml) to give after chromatography the acetoxyethyl furanone as a white solid (0.88 g, 34%) m.p. 124°C. ν_{\max} 2880, 1750, 1610, 1445, 1365, 1230, 1170, 1080, 1030, 990, 960, 930, 835, 760, 715 cm^{-1} . λ_{\max} 313 nm (e 31296). ^1H n.m.r. δ (CDCl_3) 1.53, d, J 6.2 Hz, (H_2')₃; 2.13, s, COCH_3 ; 5.66, m, 1H, H_1' ; 7.43, bs, H_4 . ^{13}C n.m.r. δ (CDCl_3): 18.9, CH_3 ; 20.9, C_2' ; 53.4, C_1' ; 81.7, 5- CHBr ; 134.6, C_4 ; 136.7, C_3 ; 149.2, C_5 ; 166.0, C_2 ; 169.6, CO. Mass spectrum: m/z 342, (M ($^{81}\text{Br}_2$), <5%); 340 (M (^{81}Br , ^{79}Br), 6); 338, (M ($^{79}\text{Br}_2$), <5); 300 (30); 299 (26); 298 (62); 297 (44); 296 (32); 295 (22); 281 (22); 279 (18); 261 (34); 259 (37); 219 (68); 217 (70); 201 (32); 200 (31); 199 (34); 174 (20); 172 (30); 170 (14); 157 (22); 145 (28); 143 (24).

EXAMPLE 5

5-(Dibromomethylene)-3-(1-thioacetoxyethyl)-2(5H)-furanone

A solution of 5-(dibromomethylene)-3-(1-bromoethyl)-2(5H)-furanone (3.00 g, 7.7 mmol) in glacial acetic acid (160 ml) containing potassium thioacetate (1.20 g, 15 mmol) was refluxed for 12h. The mixture was concentrated to approximately 20 ml and neutralised with excess saturated sodium carbonate solution. The residual oil was extracted with ether (3 x 100 ml), washed with brine, dried over sodium sulfate and evaporated. The crude product was chromatographed on silica gel using dichloromethane /

WO 99/54323

PCT/AU99/00285

15

light petroleum (1 : 1) as eluent to yield the thioacetoxyethylfuranones (0.96 g, 34%) as a yellow oil ν_{\max} 3200, 2910, 2850, 1780, 1730, 1690, 1600, 1450, 1420, 1380, 1350, 1270, 1170, 1105, 1010, 960, 880, 850, 810, 770 cm^{-1} . λ_{\max} 297 nm (e 6664). ^1H NMR d: 1.61 (d, 3H, J 7.2 Hz, H-2'); 2.52 (s, 3H, SCOCH_3); 4.49 (q, 1H, J 7.2 Hz, H-1'); 7.44 (s, 1H, H4). Mass spectrum: m/z 358 (M ($^{81}\text{Br}_2$)); 356 (M (^{81}Br , ^{79}Br)); 354 (M ($^{79}\text{Br}_2$)); 316, 314, 312, 283, 281, 279, 277, 275, 235, 233, 200, 172, 153, 143.

EXAMPLE 6**4-Bromo-5-(bromomethylene)-3-(1-acetamidobutyl)-2(5H)-furanone**

Trimethylsilyl trifluoromethanesulfonate (0.1 ml) was added with stirring to a cooled solution of 4-bromo-5-(bromomethylene)-3-(1-hydroxybutyl)-2(5H)-furanone (0.12 g, 0.37 mmol) in acetonitrile (10 ml) at -5°C . After stirring the reaction mixture at room temperature for 1h, it was quenched with water (20 ml) and extracted with ether (3 x 40 ml). The combined ether extracts was washed with brine, dried over sodium sulfate and evaporated to yield the amide as a light tan oil (0.1g, 74%).

Recrystallisation of the crude product from dichloromethane/light petroleum gave the pure amide as yellow powder, m.p. $153-55^\circ\text{C}$. ^1H n.m.r. δ (CDCl_3) 0.93, t, J 7.2 Hz, (H4')₃; 1.24-1.40, m, (H3')₂; 1.66-1.77, m, (H2')₂; 1.98, s, NHCOCH_3 ; 5.02, q, 7.9 Hz, H1'; 6.25, bd, J 8.7 Hz, NH; 6.38, s, 5-CHBr. ^{13}C n.m.r. δ (CDCl_3): 13.5, C4'; 19.0, C3'; 23.1, NHCOCH_3 ; 35.2, C2'; 45.7, C1'; 93.6, 5-CHBr; 130.9, C4; 131.9, C3; 149.6, C5; 165.3, C2; 169.6, NHCO . Mass spectrum: m/z 389, (M ($^{81}\text{Br}_2$), <5%); 367 (M (^{81}Br , ^{79}Br), <5); 365, (M ($^{79}\text{Br}_2$), <5); 362 (5); 364 (5); 326 (18); 324 (30); 322 (18); 284 (28); 282 (53); 280 (30).

EXAMPLE 7**5-(Dibromomethylene)-3-(1-hydroxyethyl)-2(5H)-furanone**

A solution of 5-(dibromomethylene)-3-(1-bromoethyl)-2(5H)-furanone (18.0 g, 0.05 mol) in a mixture of dioxane (200 ml) and sulfuric acid (3M, 35 ml) was refluxed in an oil bath for 3h. After cooling the mixture to room temperature, it was diluted with water (300 ml) and extracted with dichloromethane (3 x 200 ml). The combined dichloromethane extracts were washed with water, dried and evaporated. The crude product was purified by silica gel chromatography using dichloromethane / light petroleum (1 : 1) as an eluent to yield the hydroxyethyl furanone (9.6 g, 62%) as a white solid, m.p. 100°C . ν_{\max} 3300, 2870, 1750, 1595, 1440, 1370, 1250, 1170, 1030, 985,

PCT/AU99/00285

WO 99/54323

16

955, 835, 770, 720 cm^{-1} . λ_{max} 311 nm (e 5832). ^1H n.m.r. δ (CDCl_3) 1.50, d, J 7.2 Hz, (H_2')₃; 4.72, m, 1H, H_1' ; 7.49, bs, H_4 . ^{13}C n.m.r. δ (CDCl_3): 21.8, C_2' ; 63.4, C_1' ; 81.3, 5- CHBr ; 133.7, C_4 ; 140.3, C_3 ; 149.5, C_5 ; 167.3, C_2 . Mass spectrum: m/z 300, ($\text{M}+1$ ($^{81}\text{Br}_2$), 18%); 298 ($\text{M}+1$ (^{81}Br , ^{79}Br), 36); 296, ($\text{M}+1$ ($^{79}\text{Br}_2$), 18); 285 (22); 283 (41); 281 (28); 257 (78); 255 (100); 253 (78); 219 (15); 217 (15); 201 (22); 200 (34); 199 (36); 174 (24); 172 (38); 170 (18); 147 (21); 145 (28); 119 (38); 117 (38).

EXAMPLE 8**5-(Dibromomethylene)-3-(1-hydroxybutyl)-2(5H)-furanone**

The procedure described for 5-(dibromomethylene)-3-(1-hydroxyethyl)-2(5H)-furanone was used to treat 3-(1-acetoxybutyl)-5-(dibromomethylene)-2(5H)-furanone (0.70g, 1.9 mmol) with sulfuric acid (3 M, 5 ml) in dioxane (30 ml) to give after chromatography the hydroxybutyl furanone as a yellow oil (0.42g, 68%) ν_{max} 3441, 2960, 2931, 2873, 1779, 1615, 1267, 1174, 1020, 965, 848 cm^{-1} . λ_{max} 303.6 nm (e 1161). ^1H NMR d: 0.95 (t, 3H, $\text{H}-4'$); 1.43 (m, 2H, $\text{H}-3'$); 1.78 (m, 2H, $\text{H}-2'$); 3.22 (s, 1H, OH); 4.58 (d, 1H, $\text{H}-1'$); 7.52 (s, 1H, H_4). Mass spectrum: m/z 328 (M ($^{81}\text{Br}_2$)); 326 (M (^{81}Br , ^{79}Br)); 324 (M ($^{79}\text{Br}_2$)); 299; 297; 285; 283 (100%); 281; 257; 255; 253; 247; 245; 203; 205; 175; 173.

EXAMPLE 9**5-(Dibromomethylene)-3-(1-fluoroethyl)-2(5H)-furanone**

A cooled solution of 5-(dibromomethylene)-3-(1-hydroxyethyl)-2(5H)-furanone (0.47g, 1.6 mmol) in analytical grade dichloromethane (2 ml) was added dropwise with stirring to a solution of (diethylanino)sulfur trifluoride (1 ml) in dichloromethane (2 ml) held in a dry ice/acetone cooling bath. The progress of the reaction was monitored by thin layer chromatography. Upon completion of the reaction, the mixture was added dropwise to a conical flask containing water (100 ml). The product was extracted with dichloromethane (3 x 50 ml) and the organic layer was dried over anhydrous sodium sulfate. The crude product was chromatographed on a silica column using dichloromethane as the eluent. The fraction with R_f of 0.90 in dichloromethane was collected and evaporated to yield the fluoro compound (0.47g, 97%) as a yellow solid m.p. 41°C. ν_{max} 3096, 2924, 2854, 1790, 1754, 1609, 1463, 1376, 1264, 1192, 1092, 990, 847, 771 cm^{-1} . λ_{max} 306.4 nm (e 4269). ^1H NMR d: 1.62(m, 3H, $\text{H}-2'$); 5.34, 5.52(m, 1H, $\text{H}-1'$ (CHF)); 7.58(s, 1H, 5- CHBr). ^{13}C n.m.r. δ (CDCl_3): 19.7 and 19.8, C_2' ; 82.3, CBr_2 ; 83.4 and

PCT/AU99/00285

WO 99/54323

17

85.6, C1': 134.4, C4; 136.5 and 138.5, C3; 149.2, C5; 165.7, CO. Mass spectrum: m/z 302 (M(⁸¹Br₂); 300 (M(⁸¹Br, ⁷⁹Br); 298 (M(⁷⁹Br₂); 202; 200; 198; 175 (100%); 172; 170.

EXAMPLE 10**5-(Dibromomethylene)-3-(1-fluorobutyl)-2(5H)-furanone**

The procedure described for 5-(dibromomethylene)-3-(1-fluoroethyl)-2(5H)-furanone was used to treat 5-(dibromomethylene)-3-(1-hydroxybutyl)-2(5H)-furanone (0.24g, 0.74 mmol) with (diethylamino)sulfur trifluoride (1.0 ml) in dichloromethane (3 ml) to give after chromatography the fluorobutyl furanone as a pale yellow oil (0.23g, 97%) ν_{\max} 3084, 2961, 2874, 1780, 1614, 1465, 1379, 1266, 1180, 1026, 966, 847, 784, 680 cm⁻¹. λ_{\max} 308.6nm (e 24923). ¹H NMR d: 0.95 (t, 3H, H-4'); 1.52 (m, 2H, H-3'); 1.88 (m, 2H, H-2'); 5.2, 5.4 (m, 1H, H-1'(CHF)); 7.56 (s, 1H, 5-CHBr). ¹³C n.m.r. δ (CDCl₃): 13.5, C4'; 17.8, C3'; 35.6 and 35.9, C2'; 82.1, 5-CBr₂; 86.5 and 88.8, C1'; 134.8, C4; 135.7 and 135.7 and 136.0, C3; 149.3, C5; 165.7 and 165.8, CO. Mass spectrum: m/z 330 (M(⁸¹Br₂); 328 (M(⁸¹Br, ⁷⁹Br); 326 (M(⁷⁹Br₂); 288; 286; 284; 247 (100%); 207; 205.

EXAMPLE 11**4-Bromo-5-(bromomethylene)-3-(1-butanoyloxybutyl)-2(5H)-furanone**

4-Bromo-5-(bromomethylene)-3-(1-hydroxybutyl)-2(5H)-furanone (4.75 g, 0.015 mol) and butanoyl chloride (7.8 ml, 0.075 mol) were refluxed together for 7h then cooled and poured into water (50 ml) and extracted with ether (3 x 30 ml). The combined ether extracts were washed sequentially with saturated sodium bicarbonate (2 x 50 ml) and brine (50 ml), dried over sodium sulfate, and evaporated. The crude product was purified by silica gel chromatography using ether / light petroleum (1 : 9) as the eluent to yield the butanoyloxybutyl furanone as a pale yellow oil (3.60 g, 30%). ν_{\max} 2950, 1780, 1730, 1635, 1600, 1450, 1380, 1280, 1240, 1165, 1060, 980, 840, 770 cm⁻¹. λ_{\max} 289 nm (e 14900). ¹H n.m.r. δ (CDCl₃) 0.91, t, J 7.4 Hz, OCOCH₂CH₂CH₃; 0.93, t, J 7.2 Hz, (H4')₃; 1.35, m, (H3')₂; 1.66, q, J 7.4 Hz, OCOCH₂CH₂CH₃; 1.80-1.95, m, (H2')₂; 2.32, t, J 7.4 Hz, OCOCH₂CH₂CH₃; 5.50, dd, J 6.4 Hz 8.0 Hz, H1'; 6.36, s, 5-CHBr. ¹³C n.m.r. δ (CDCl₃): 13.4, OCOCH₂CH₂CH₃; 13.5, C4'; 18.2, OCOCH₂CH₂CH₃; 18.4, C3'; 33.5, C2'; 35.7, OCOCH₂CH₂CH₃; 68.0, C1'; 93.2, 5-CHBr; 130.6, C4; 132.4, C3; 149.6, C5; 165.9, C2; 172.7, CO. Mass spectrum: m/z 399, (M+1 (⁸¹Br₂), <5%); 397 (M+1 (⁸¹Br, ⁷⁹Br), <5); 395, (M+1 (⁷⁹Br₂), <5); 327 (18); 325 (28); 323 (18);

WO 99/54323

PCT/AU99/00285

18

317 (26); 315 (26); 311 (8); 309 (16); 307 (8); 283 (16); 281 (34); 279 (16); 267 (42); 265 (40); 247 (16); 245 (16); 223 (56); 221 (44).

EXAMPLE 12

4-Bromo-5-(bromomethylene)-3-(1-octadecanoyloxybutyl)-2(5H)-furanone

4-Bromo-5-(bromomethylene)-3-(1-hydroxybutyl)-2(5H)-furanone (0.24 g, 0.7 mmol) and octadecanoyl chloride (0.3 ml, prepared from octadecanoic acid and thionyl chloride) were stirred in an oil bath at 110°C for 24 h. The reaction mixture was diluted with ether (50 ml) and washed with water (3 x 20 ml) followed by brine (30 ml). The organic phase was dried over sodium sulfate and evaporated to yield a brown oil. The crude product was purified by silica gel chromatography using dichloromethane as the eluent to yield the octadecanoyloxybutyl furanone as dark tan oil (0.14 g, 32%). ¹H n.m.r. δ (CDCl₃) 0.87, t, J 7.2 Hz, OCO(CH₂)₁₆CH₃; 0.95, t, J 7.2 Hz, (H_{4'})₃; 1.28, m, OCOCH₂(CH₂)₁₅CH₃; 1.35-1.45, m, (H_{3'})₂; 1.58-1.60, m, OCOCH₂CH₂; 1.75-2.05, m, (H_{2'})₂; 2.34, t, J 7.2 Hz, OCOCH₂(CH₂)₁₅CH₃; 5.43, dd, J 6.2 Hz 7.7 Hz, H_{1'}; 6.37, s, 5-CHBr. ¹³C n.m.r. δ (CDCl₃): 13.5, OCC(CH₂)₁₆CH₃; 14.1, C_{4'}; 18.6, 22.7, 24.8, 29.2, 29.3, 29.4, 29.6, 29.7, 31.9, 33.8, 33.8, CH₂; 68.0, C_{1'}; 93.3, 5-CHBr; 130.7, C₄; 131.3, C₃; 149.8, C₅; 163.7, C₂; 173.1, CO.

EXAMPLE 13

Method A

4-Bromo-5-(bromomethylene)-3-(1-acryloyloxybutyl)-2(5H)-furanone

The procedure described for 4-bromo-5-(bromomethylene)-3-(1-butanoyloxybutyl)-2(5H)-furanone was used to treat 4-bromo-5-(bromomethylene)-3-(1-hydroxybutyl)-2(5H)-furanone (4.75 g, 0.015 mol) with acryloyl chloride (6.0 ml, 0.073 mol). The crude product was purified by silica gel chromatography using ether / light petroleum (1 : 9) as the eluent to yield the acryloyloxybutyl furanone as a pale yellow oil (3.60 g, 60%).
 ν_{\max} 3060, 2940, 2850, 1770, 1710, 1620, 1590, 1430, 1390, 1385, 1280, 1250, 1160, 1095, 1030, 970, 835, 795, 760, 700 cm⁻¹. λ_{\max} 293 nm (e 18170). ¹H n.m.r. δ (CDCl₃) 0.91, t, J 7.4 Hz, ester CH₃; 0.97, t, J 7.4 Hz, (H_{4'})₃; 1.38, m, (H_{3'})₂; 1.84-2.04, m, (H_{2'})₂; 5.63, dd, J 6.7 Hz 8.2 Hz, H_{1'}; 5.88, d, J 10.7 Hz, CH=CH₂; 6.14, dd, J 10.7 Hz 16.3 Hz, CH=CH₂; 6.39, s, 5-CHBr; 6.48, d, J 16.3 Hz, CH=CH₂. ¹³C n.m.r. δ (CDCl₃): 13.5, C_{4'}; 18.5, C_{3'}; 33.7, C_{2'}; 68.2, C_{1'}; 93.5, 5-CHBr; 127.5, CH=CH₂; 130.4, C₄; 131.5, CH=CH₂; 132.1, C₃; 149.8, C₅; 163.7, C₂; 165.2, CO. Mass spectrum: m/z 382, (M (⁸¹Br₂), <5%); 380 (M (⁸¹Br, ⁷⁹Br), <5); 378, (M (⁷⁹Br₂), <5); 327 (14); 325 (28); 323 (14);

WO 99/54323

PCT/AU99/00285

19

301 (16); 299 (16); 283 (8); 281 (12); 279 (8); 269 (12); 267 (24); 265 (12); 229 (18); 227 (24); 225 (18); 223 (20); 203 (34); 201 (46); 175 (32); 173 (48); 147 (38); 145 (46); 143 (48).

Method B

Concentrated sulfuric acid (1 drop) was added to a solution of 4-bromo-5-(bromomethylene)-3-(1-hydroxybutyl)-2(5H)-furanone (0.94 g, 3.0 mmol) and acrylic acid (2 ml) in benzene (5 ml). The mixture was refluxed for 4 h, and after cooling to room temperature, poured into water (50 ml). The crude product was extracted with ether (2 x 50 ml), and the combined ether extract washed with sodium carbonate solution. The extract was dried over anhydrous sodium sulfate, evaporated and chromatographed over silica column using dichloromethane/light petroleum as the eluent to yield the pure acryloyloxybutyl furanone as a tan oil (0.48 g, 42%).

EXAMPLE 14

4-Bromo-5-(bromomethylene)-3-(1-butanoyl)-2(5H)-furanone

To an ice cooled solution of 4-bromo-5-(bromomethylene)-3-(1-hydroxybutyl)-2(5H)-furanone (2.77 g, 8.5 mmol) in acetone (75 ml) was added dropwise with stirring Jones reagent (12 ml, prepared by dissolving chromium trioxide (13.36 g) in sulfuric acid (11.2 ml) and water (38.5 ml). The mixture was stirred at room temperature for 1h and the progress of the reaction monitored by thin layer chromatography. After the completion of the reaction, the mixture was poured into water (200 ml) and extracted with ether (3 x 100 ml). The combined ether extracts were washed with brine (100 ml), dried over sodium sulfate and evaporated to yield the crude ketone (2.23g, 81%) as a yellow solid. Recrystallisation of the crude ketone from dichloromethane/hexane gave the pure ketone as yellow plates, m.p. 83-84°C ν_{\max} 1700, 1680, 1630, 1540, 1310, 1000 cm^{-1} . ^1H n.m.r. δ (CDCl_3) 0.97, t, J 7.2 Hz, (H_4')₃; 1.70, m, (H_3')₂; 2.93, t, J 7.2 Hz, (H_2')₂; 6.74, s, 5-CHBr. ^{13}C n.m.r. δ (CDCl_3): 13.6, C4'; 16.7, C3'; 44.4, C2'; 99.3, 5-CHBr; 125.7, C4; 138.1, C3; 150.4, C5; 163.5, CO; 194.1, C1'. Mass spectrum: m/z 326, (M ($^{81}\text{Br}_2$), <5%); 324 (M (^{81}Br , ^{79}Br), 5); 320, (M ($^{79}\text{Br}_2$), <5); 298 (10); 296 (22); 281 (16); 279 (8); 225 (4); 131 (14); 77 (32); 71 (52), 43 (100).

Covalently Bound Furanone Polymer Synthesis

EXAMPLE 15

Preparation of furanone acrylate homopolymer

WO 99/54323

PCT/AU99/00285

20

A mixture of 4-bromo-5-(bromomethylene)- and 5-(dibromomethylene)-3-(1-acryloyloxybutyl)-2(5H)-furanone (0.36 g), AIBN (0.003 g) and toluene (0.75 ml) was degassed and then heated at 60°C for 24h. Hexane was added to the mixture and the precipitated polymer was washed once with methanol. The final product was collected and dried to yield the polymer (0.04 g, 11% conversion) of average mass 14284.

EXAMPLE 16**Preparation of furanone acrylate-polymethyl methacrylate copolymer**

A mixture of methyl methacrylate (3.0 g), 4-bromo-5-(bromomethylene)- and 5-(dibromomethylene)-3-(1-acryloyloxybutyl)-2(5H)-furanone (0.74 g) and AIBN (0.006 g) was degassed for 1/2h by purging with nitrogen gas and then heated at 60°C for 24h. Hexane (50 ml) was added to the mixture and the precipitated polymer was washed once with methanol. The polymer was further purified by reprecipitation from chloroform and excess methanol. The final product was collected and dried to yield the polymer (1.74 g, 47% conversion) of average mass 7578.

EXAMPLE 17**Preparation of furanone acrylate-polystyrene copolymer**

A mixture of styrene (15 g), 4-bromo-5-(bromomethylene)- and 5-(dibromomethylene)-3-(1-bromoethyl)-2(5H)-furanone (0.16 g) and AIBN (0.023 g) was degassed for 1/2h by purging with nitrogen gas and then heated at 60°C for 3h. After the completion of polymerisation, the mixture was poured into hexane and the precipitated polymer was washed twice with ether and dried in vacuo (0.1 mm Hg) at 40°C for 24h to yield the polymer (12.9 g, 85% conversion). An XPS analysis of the powdered polymer in aluminium foil confirmed the presence of bromine.

EXAMPLE 18**Preparation of furanone acrylate-poly(Styrene/HEMA/MMA) polymer**

To a solution of styrene (5 g), MMA (5 g) and HEMA (5 g) in toluene (8 ml) was added 4-Bromo-5-(bromomethylene)- and 5-(dibromomethylene)-3-(1-bromoethyl)-2(5H)-furanone (0.15 g) followed by dodecanethiol (2 ml) and AIBN (0.4 g). The mixture was degassed by two freeze-thaw cycles and then heated at 70°C for 24h. After the completion of polymerisation, the mixture was treated with hexane and the precipitated polymer was washed with hexane and dried in vacuo (0.1mm Hg) at room temperature for 24h to yield the polymer (22.2 g, 87% conversion).

WO 99/54323

PCT/AU99/00285

21

EXAMPLE 19**4-Bromo-5-(bromomethylene)-3-(1-butenyl)-2(5H)-furanone**

Concentrated sulfuric acid (2 drops) was added to a solution of 4-bromo-5-(bromomethylene)-3-(1-hydroxybutyl)-2(5H)-furanone (2.0 g) in toluene (10 ml). The mixture was refluxed for 4h, and after cooling to room temperature, poured into water (50 ml). The crude product was extracted with ether (2 x 50 ml), and combined ether extract washed with sodium carbonate solution. The extract was dried over sodium sulfate, evaporated and chromatographed over silica column using light petroleum as the eluent to yield the pure 3-(1-1-butenyl)-furanone as a light yellow oil (0.40 g). ¹Hnmr δ (CCl₃) 1.10, t, J 7.2 H₂, (H4')₃; 2.26, q, J 7.2 H₂, (H3')₂; 6.20, d, CH=CH; 7.20, d, CH=CH, 6.24, s, 5-CHBr

Fimbrilide Biological Activity**MATERIALS AND METHODS****Inhibition of Cyprid Settlement**

The effects of synthetic furanones on the settlement of barnacle larvae were tested using cyprids of the cosmopolitan fouling barnacle *Balanus amphitrite* Darwin. The naturally occurring furanone 2, and the synthetically prepared compounds 281 (a 1:1:1 mixture of synthesised 2 & 8 & 1), 2223 (a 1:1 mixture of synthesised 22 & 23), 2425 (a 1:1 mixture of synthesised 24 & 25), 26, 27, and 28 (Figure 1) were compared for their efficacy in deterring barnacle cyprid settlement. Compounds were dissolved in ethanol (99.7% + purity) at a concentration of 180 µg.ml⁻¹ to 1.8 µg.ml⁻¹. A 0.5 ml aliquot of each compound to be tested was added to treatment petri dishes (surface area 9 cm²), and 0.5 ml of ethanol only was added to ethanol control dishes. Dishes were dried on a shaker resulting in a coating of extract on treatment dishes with a concentration range of 10 µg.cm⁻² to 100 ng.cm⁻² for each compound.

Cypris larvae were obtained from laboratory cultures of adult brood stock of *Balanus amphitrite*. Nauplii of *B. amphitrite* were collected and reared on *Skeletonema costatum* until reaching cyprid stage. Cypris larvae were filtered and maintained in filtered seawater at 5°C for five days prior to use in settlement assays (Rittschof *et al.*, 1992).

WO 99/54323

PCT/AU99/00285

22

Settlement tests were conducted by adding 25-35 cyprids to either treatment dishes, ethanol control dishes, or untreated dishes, each containing 4 ml of sterilised filtered seawater ($0.22 \mu\text{m}$). All the treatments and controls were tested in triplicate. Test dishes were incubated for 24 h at 28°C in a 15:9 h light-dark cycle (Rittschof *et al.*, 1992). After 24 h, the test was terminated by the addition of three drops of 40% formaldehyde, and non-settled larvae filtered from the dish. The percent settlement of cyprids was then determined by counting settled and non-settled larvae.

Statistical Analyses

The data from the bioassays were analysed by analysis of variance (ANOVA) followed by Tukey's multiple comparison test. Data were analysed as percentages after arcsin \bar{A}_p transformations.

RESULTS

Inhibition of Cyprid Settlement

The settlement of *Balanus amphitrite* Cypris larvae was significantly inhibited by the compounds tested (Figure 2; two-factor ANOVA [metabolite x concentration] followed by Tukey's test). All treatments completely inhibited settlement at the highest concentration ($10 \mu\text{g.cm}^{-2}$). Ethanol controls were used in the analysis as ethanol had no significant effect on settlement (single factor ANOVA, $P=0.17$). The synthetic furanone 2223 (Figure 1) was the most active metabolites (Figure 2). At a concentration of $1 \mu\text{g.cm}^{-2}$ 2223 completely inhibited settlement and inhibited settlement by 80% compared to the control at 500 ng.cm^{-2} . The next most inhibitory compound was the furanone 28 (Figure 1) which inhibited settlement completely at $5 \mu\text{g.cm}^{-2}$ and inhibited settlement by 90% at $1 \mu\text{g.cm}^{-2}$. A group of furanones, 2425, 26 and 27 completely inhibited settlement at $5 \mu\text{g.cm}^{-2}$ but had no effect at $1 \mu\text{g.cm}^{-2}$. The furanone 2 and the synthetic analogue 281, a 1:1:1 mixture of 2, 8 and 1 (Figure 1) were the least effective compounds completely inhibiting settlement at $10 \mu\text{g.cm}^{-2}$.

Inhibition of *Staphylococcus aureus*

Staphylococcus aureus is a facultatively anaerobic, nonmotile, gram-positive coccus and is normally associated with the skin, skin glands, and mucous membranes of humans. *S. aureus* is the most important human staphylococcal pathogen and causes, for example, boils, abscesses and wound infections.

WO 99/54323

PCT/AU99/00285

23

A screening experiment of the different furanones against the growth of *S. aureus* was performed in a BioRad 3550 Microplate reader. The growth was measured as absorbance at 610 nm up to 9 h. A complex growth media, Nutrient Broth, was used and the cells were grown at 37°C. Both natural furanones (compounds 2, 3 and 4) and synthesised furanones (compounds 33/34 and 45) were used in the experiment at the concentration 10 µg/ml.

The results showed that the synthesised furanones (33/34 and 45) inhibited growth of *S. aureus* more effectively than the natural furanones (Figure 3). The growth of the cells inoculated with 33/34 and 45 was completely inhibited for 9 h compared to 2 h for those inoculated with the natural compounds. All furanones, however, inhibited the growth of *S. aureus* compared to the control.

Further experiments were performed with the synthesised furanones 45 and 33/34 at the concentrations 10 µg/ml and 5 µg/ml. The cells were grown in side arm flasks in NB media at 37°C. The growth of the cells were measured at 610 nm for up to 48 h.

The results showed that compound 33/34 was more effective at inhibiting growth of *S. aureus* compared to compound 45 (Figure 4), however, both compounds at both concentrations inhibited the growth completely for 9 h. Growth of the cells occurred after 9h with compound 45 at the concentration 5µg/ml and after 15 h at the concentration 10 µg/ml. Compound 33/34 at 5µg/ml inhibited the growth for 15 h and at the concentration 10 µg/ml the growth of *S aureus* was completely inhibited for 34 h.

DISCUSSION

The derivatisation of naturally occurring furanones resulted in an increase in the deterrence of barnacle settlement. For example, manipulation of the length of the acyl side chain and the functionality on the 1' position of the acyl side chain of the furanone resulted in a significant increase in activity. This is clearly demonstrated in a comparison of the activity of furanones 2 and 2425. In 2425 a bromine has been added in the 1' position of acyl chain resulting in a five fold increase in activity in the settlement bioassay (Figure 2). All of the synthesised furanones are either novel compounds not being previously reported in the literature or are racemic mixtures of a naturally occurring furanone. The racemic analogues of the naturally occurring compounds have the same activity as the naturally

WO 99/54323

PCT/AU99/00285

24


occurring optically pure form. Therefore, the synthetic furanones, both analogues of naturally occurring compounds and novel compounds, have activity comparable to or better than the compounds from which their structure was derived, e.g. furanone 2 vs 2425.

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

Article 34
21/12/99

25

1. A compound according to formula (I):



(I)

5

wherein R_6 is H, OH, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl
whether unsubstituted or substituted, straight chain or branched chain,
hydrophobic, hydrophilic or fluorophilic;

10

R_2 and R_3 are independently or both H or halogen;

R_9 is halogen;

Z is independently selected from the group R_6 , halogen, OOH,
 $OC(O)R_6$, = O, amine, azide, thiol, mercaptoalkyl, alkenyloxy,

15

mercaptoalkenyl, aryloxy, mercaptoaryl, arylalkyloxy, mercaptoarylalkyl,
 $SC(O)R_6$, $OS(O)R_6$, $OS(O)_2R_6$, $NHC(O)R_6 = NR_4$ or NHR_4 ; and

R_4 is OH, alkyl, alkoxy, poly(ethylene glycol), alkenyl, aryl or arylalkyl.
provided that:

when R_6 is propyl, R_2 is Br, R_3 is H or Br and R_9 is Br, then Z is other
than H, $OC(O)CH_3$ or OH;

20

when R_6 is propyl, R_2 is Br, R_3 is H and R_9 is I, then Z is other than
 $OC(O)CH_3$ or OH;

when R_6 is propyl, R_2 is Br, R_3 is H and R_9 is Cl, then Z is other than
OH;


25

when R_6 is propyl, R_2 is H, R_3 and R_9 are Br, then Z is other than H; and
when R_6 is propyl, R_2 is Br, R_9 is Cl and Z is H, then R_3 is other than Cl.

2. A compound according to claim 1 of formula (Ia):

Article 34
2/12/99

26



(Ia)

wherein R_1 is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

X is a halogen, OH, OOH, $OC(O)R_1$ or $=O$;

R_2 and R_3 are independently or both hydrogen or halogen; and


R_9 is halogen, provided that:

when R_1 is propyl, R_2 is Br, R_3 is H or Br and R_9 is Br, then X is other than $OC(O)CH_3$ or OH;

when R_1 is propyl, R_2 is Br, R_3 is H and R_9 is I, then X is other than $OC(O)CH_3$ or OH;

when R_1 is propyl, R_2 is Br, R_3 is H, R_9 is Cl, then X is other than OH.

3. A compound according to claim 1 of formula (II):



(II)

wherein R_1 is hydrogen, unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl;

R_2 and R_3 are independently or both hydrogen or halogen;

R_9 is halogen; and

R_4 is selected from the group halogen, amine, azide, hydroxyl, thiol, or any hydrophobic, hydrophilic or fluorophilic alkyl, alkoxy, mercaptoalkyl,

Article 34
21/12/99

27

alkenyloxy, mercaptoalkenyl, aryloxy, mercaptoaryl, arylalkyloxy,
mercaptoarylalkyl, OC(O)R_1 , SC(O)R_1 , OS(O)R_1 , $\text{OS(O)}_2\text{R}_1$, NHC(O)R_1 ,
 OC(O)NHR_1 , or $=\text{O}$, provided that:

when R_4 is propyl, R_2 is Br, R_3 is H or Br, and R_6 is Br, then R_1 is other
than H, OC(O)CH_3 or OH;


when R_4 is propyl, R_2 is Br, R_3 is H, R_6 is I, then R_1 is other than
 OC(O)CH_3 or OH;

when R_4 is propyl, R_2 is Br, R_3 is H, R_6 is Cl, then R_1 is other than OH;

when R_4 is propyl, R_2 is H, R_3 and R_6 are Br, then R_1 is other than H;

when R_4 is propyl, R_2 is Br, R_3 and R_6 are Cl, then R_1 is other than H.

4. A compound according to claim 1 of formula (III):



(III)

wherein R_2 and R_3 are independently or both hydrogen or halogen;

R_5 is OH or the same as R_1 ;



R_6 is halogen; and

R_1 is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl
whether unsubstituted or substituted, straight chain or branched chain,
hydrophobic, hydrophilic or fluorophilic.


5. A compound according to claim 1 of formula (IV) or (V):

Article 34
2/12/99

28



- wherein R_1 is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;
- R_2 and R_3 are independently or both hydrogen or halogen;
- R_8 is halogen and
- R_9 is OH, NHR_1 , $NHC(X)NH_2$, $NHC(X)NHR_1$ ($X=O, S, NR_1$) or any R_1 .
6. A method for forming a fimbrolide derivative, the method including reacting a fimbrolide with a halogenating agent and/or an oxygenating agent to form compounds with formula (Ia):



- wherein R_1 is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;
- X is a halogen ($X = F, Cl, Br$ or I), OH, OOH, $OC(O)R_1$ or $=O$;
- R_2 and R_3 are independently or both hydrogen or halogen; and
- R_9 is halogen.


Article 34
2/12/99

29

7. A method according to claim 6 wherein the halogenating agent is selected from the group N-bromosuccinimide, N-chlorosuccinimide, N-iodosuccinimide, bromine, cupric bromide, and phenyltrimethylammonium perbromide.

8. A method according to claim 6 wherein the oxygenating agent is selected from lead tetraacetate, Rose Bengal/oxygen gas, hydrogen peroxide/vanadium pentoxide, selenium dioxide, and 3-chloroperoxybenzoic acid.

9. A method for forming a fimbrolide derivative, the method including displacement and/or functionalisation of the halogen or oxygen substituent in the fimbrolide side chain by treating with a nucleophile or an electrophile to form compounds with formula (II):



(II)

wherein R_1 is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

R_2 and R_3 are independently or both hydrogen or halogen;

R_4 is halogen; and


R_1 is selected from the group halogen, amine, azide, hydroxyl, thiol, or any hydrophobic, hydrophilic or fluorophilic alkyl, alkoxy, mercaptoalkyl, alkenyloxy, mercaptoalkenyl, aryloxy, mercaptoaryl, arylalkyloxy, mercaptoarylalkyl, $OC(O)R_1$, $SC(O)R_1$, $OS(O)R_1$, $OS(O)_2R_1$, $NHC(O)R_1$, $OC(O)NHR_1$, or $=O$ provided that when R_4 is propyl, R_2 is Br, R_3 and R_4 are Cl, then R_1 is other than H.

30

10. A method according to claim 9 wherein the nucleophile is selected from metal halides, water, organic metal carboxylate, organic alcohols, dimethyl sulfoxide, and organonitrile/acid catalyst, and silver triflate.

5 11. A method according to claim 9 wherein the electrophile is selected from organic acids, isocyanates, acid halides or active acylating agents such as carbonyl imidazoles or anhydrides (including activated hydrophilic PEG acids, PEG acid chlorides, PEG-oxycarbonylimidazoles and PEG-isocyanates) organic sulfonyl chlorides, and diethylaminosulfur trifluoride.

10 12. A method for forming a fimbrolide derivative the method including reacting an hydroxyl substituent in the fimbrolide side chain with an oxidising agent to form a compound in accordance with formula (III):



15

wherein R_2 and R_3 are independently or both hydrogen or halogen;

R_5 is OH or the same as R_1 ;

R_9 is halogen; and :

20


R_1 is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic.

25 13. A method according to claim 12 wherein the oxidising agents is selected from the group consisting of acid dichromate reagents in any form which may be free or polymer supported, chromium trioxide, manganese dioxide, potassium permanganate, selenium dioxide, ceric ammonium nitrate, ruthenium tetroxide, and hot nitric acid.

31

14. A method according to claim 13 wherein the acid dichromate agent is selected from the group consisting of Jones reagent, pyridinium chlorochromate, pyridinium dichromate.

15. A method for forming a fimbrolide analogue derived from a compound of formula (III)



(III)

5

wherein R₂ and R₃ are independently or both hydrogen or halogen;
R₅ is OH or the same as R₁;


R₆ is halogen; and

10


R₁ is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic,

the method including reacting an aldehyde or ketone substituent in the fimbrolide side chain of the compound with an amine derivative to form a compound with formula (IV) or (V):

15



(IV)



(V)

wherein R_1 is hydrogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

R_2 and R_3 are independently or both hydrogen or halogen;


5 R_4 is halogen and

R_5 is OH, NHR_1 , $NHC(X)NH_2$, $NHC(X)NHR_1$ ($X=O, S, NR_1$) or any R_1 .

16. A method according to claim 15 wherein the amine derivative is selected from the group hydroxyl amine hydrochloride, alkyl and aryl hydrazines, alkyl or aryl amine optionally in the presence of a reducing agent.

17. A fimbrolide derivative produced by a method in accordance with any one of claims 6 to 16.

18. An oligomer or polymer formed by oligomerisation or polymerisation of a fimbrolide compound of the formula:



10

wherein R_6 is H, OH, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

15 R_2 and R_3 are independently or both H or halogen;

R_4 is halogen;

Z is independently selected from the group R_6 , halogen, OOH,

$OC(O)R_6$, $=O$, amine, azide, thiol, mercaptoalkyl, alkenyloxy,

mercaptoalkenyl, aryloxy, mercaptoaryl, arylalkyloxy, mercaptoarylalkyl,

20 $SC(O)R_6$, $OS(O)R_6$, $OS(O)_2R_6$, $NHC(O)R_6 = NR_4$ or NHR_4 ; and

R_4 is OH, alkyl, alkoxy, poly(ethylene glycol), alkenyl, aryl or arylalkyl.

optionally with at least one other monomer.

19. A polymer according to claim 18 wherein the polymer is a homopolymer of the fimbrolide compound of claim 16.

20. A polymer according to claim 18 wherein the polymer is a copolymer of at least one fimbrolide compound in accordance with claim 18 and at least one other polymerisable monomers.


21. Use of a compound in accordance with any one of claims 1 to 5 or 17 as antimicrobial, antiseptic, microbacterial static and/or antifouling agent.

22. An antimicrobial, antiseptic and/or microbacterial static composition including at least one compound in accordance with claims 1 to 5 or 17, or an oligomer or polymer according to any one of claims 18 to 20.

23. An antifouling composition including at least one compound in accordance with claims 1 to 5 or 17, or an oligomer or polymer according to any one of claims 18 to 20.

24. A surface coating composition incorporating at least one compound according to any one of claims 1 to 5 or 17 or an oligomer or polymer according to any one of claims 18 to 20.

25. A compound of formula (VI):



(VI)

5

wherein R₁ is alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl unsubstituted or substituted, straight chain or branched chain, hydrophobic, hydrophilic or fluorophilic;

Article 34
2/12/99

34

R₂ and R₃ are independently or both hydrogen or halogen; and
R₄ is halogen.

26. A compound according to claim 25 which is 4-Bromo-5-(bromomethylene)-3-(1-butenyl)-2(5H)-furanone.

09/673305

WO 99/54323

9 / 14

PCT/AU99/00285




Figure 5D

SUBSTITUTE SHEET (Rule 26) (RO/AU)




Figure 5E

SUBSTITUTE SHEET (Rule 26) (RO/AU)

09/673305

WO 99/54323

11 / 14

PCT/AU99/00285




Figure 5F

SUBSTITUTE SHEET (Rule 26) (RO/AU)

09/673305

WO 99/54323

12 / 14

PCT/AU99/00285





49	
50	DEDICO 5981 (CASTOR OIL) 
51	
52	

Figure 5G

SUBSTITUTE SHEET (Rule 26) (RO/A1)

09/673305

WO 99/54323

13 / 14

PCT/AU99/00285




Figure 5H.

SUBSTITUTE SHEET (Rule 26) (RO/AU)

09/673305

WO 99/54323

PCT/AU99/00285

14 / 14




Figure 51
SUBSTITUTE SHEET (Rule 26) (RO/AU)

09/6.3305

WO 99/54323

PCT/AU99/00285

1 / 14




Figure 1

SUBSTITUTE SHEET (Rule 26) (RO/AU)

WO 99/54323

PCT/AU99/00285

2 / 14




Figure 2

SUBSTITUTE SHEET (Rule 26) (RO/AU)

WO 99/54323

PCT/AU99/00285

3 / 14


Growth curves of *Staphylococcus aureus* against different furanones

Figure 3

SUBSTITUTE SHEET (Rule 26) (RO/AU)

WO 99/54323

PCT/AU99/00285

4 / 14




Figure 4

SUBSTITUTE SHEET (Rule 26) (RO/AU)

WO 99/54323

5 / 14

PCT/AU99/00285




Compound	Structure
3 (d5)	
4 (d19)	
5 (d14)	

Figure 5

SUBSTITUTE SHEET (Rule 26) (RO/AU)

WO 99/54323

6 / 14

PCT/AU99/00285






10 (d16)	 <chem>CC[C@H](C(=O)OC)C1=C(Br)OC(=O)C1=C(Br)C</chem>
20	 <chem>CC[C@H](Br)C1=C(Br)OC(=O)C1=C(Br)C</chem>
21	 <chem>CC[C@H](C(=O)OC)C1=C(Br)OC(=O)C1=C(Br)C</chem>
22	 <chem>CC[C@H](C(=O)OC)C1=C(Br)OC(=O)C1=C(C)C</chem>
23	 <chem>CC[C@H](C(=O)OC)C1=C(C)OC(=O)C1=C(Br)C</chem>

Figure 5A

SUBSTITUTE SHEET (Rule 26) (RO/AU)

09/673305

WO 99/54323

7 / 14

PCT/AU99/00285






24	
25	
26	
27	
28	

Figure 5B

SUBSTITUTE SHEET (Rule 26) (RO/AU)

09/673305

WO 99/54323

8 / 14

PCT/AU99/00285




Figure 5C

SUBSTITUTE SHEET (Rule 26) (RO/AU)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.